<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006197.pub2" GROUP_ID="SCHIZ" ID="394106071705495436" MERGED_FROM="" MODIFIED="2012-01-18 21:26:56 +0100" MODIFIED_BY="Claire Irving" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-11-05 15:46:58 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="1" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2012-01-18 21:26:56 +0100" MODIFIED_BY="Claire Irving">
<TITLE>Testosterone for schizophrenia</TITLE>
<CONTACT MODIFIED="2012-01-18 21:26:56 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="E745D7DA82E26AA201E74FE9D9D40005" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Alby</FIRST_NAME><LAST_NAME>Elias</LAST_NAME><POSITION>Assistant Professor of Psychiatry</POSITION><EMAIL_1>alby.elias@rediffmail.com</EMAIL_1><ADDRESS><ORGANISATION>Jubilee Mission Medical College</ORGANISATION><ADDRESS_1>Thrissur</ADDRESS_1><CITY>Kerala</CITY><COUNTRY CODE="IN">India</COUNTRY><PHONE_1>0091 9847238804</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-01-18 21:26:56 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="E745D7DA82E26AA201E74FE9D9D40005" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Alby</FIRST_NAME><LAST_NAME>Elias</LAST_NAME><POSITION>Assistant Professor of Psychiatry</POSITION><EMAIL_1>alby.elias@rediffmail.com</EMAIL_1><ADDRESS><ORGANISATION>Jubilee Mission Medical College</ORGANISATION><ADDRESS_1>Thrissur</ADDRESS_1><CITY>Kerala</CITY><COUNTRY CODE="IN">India</COUNTRY><PHONE_1>0091 9847238804</PHONE_1></ADDRESS></PERSON><PERSON ID="256861FF82E26AA2000C5DBBA90D3F17" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ajit</FIRST_NAME><LAST_NAME>Kumar</LAST_NAME><EMAIL_1>ajitkdrmr@yahoo.com</EMAIL_1><MOBILE_PHONE>+44 7525244559</MOBILE_PHONE><ADDRESS><DEPARTMENT>School of Medicine</DEPARTMENT><ORGANISATION>University of Leeds</ORGANISATION><ADDRESS_1>5 Willow Avenue</ADDRESS_1><CITY>Leeds</CITY><ZIP>LS4 2HF</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 7525244559</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-05 15:20:07 +0000" MODIFIED_BY="Bethany York" NOTES="&lt;p&gt;Minor update: 4/11/07&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 1/10/07&lt;/p&gt;&lt;p&gt;Conclusions changed: 2/4/07&lt;/p&gt;" NOTES_MODIFIED="2008-11-05 15:20:07 +0000" NOTES_MODIFIED_BY="Bethany York">
<UP_TO_DATE>
<DATE DAY="21" MONTH="5" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="10" MONTH="1" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="21" MONTH="5" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2012-01-18 21:26:56 +0100" MODIFIED_BY="Claire Irving" NOTES="&lt;p&gt;Three studies included in this first 2007 publication.&lt;/p&gt;"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-01-18 21:26:56 +0100" MODIFIED_BY="Claire Irving"><DATE DAY="18" MONTH="1" YEAR="2012"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>

</WHATS_NEW>
<HISTORY MODIFIED="2012-01-18 21:26:56 +0100" MODIFIED_BY="Claire Irving"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-01-18 21:26:56 +0100" MODIFIED_BY="Claire Irving"><DATE DAY="11" MONTH="11" YEAR="2009"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-11-11 12:43:58 +0100" MODIFIED_BY="Claire Irving">
<DATE DAY="5" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="21" MONTH="5" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Jubille Mission Medical College, Thrissur, Kerala</NAME>
<COUNTRY CODE="IN">India</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>South Asian Cochrane Network</NAME>
<COUNTRY CODE="IN">India</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-05 15:38:53 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-11-05 15:22:10 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-11-05 15:22:10 +0000" MODIFIED_BY="[Empty name]">Testosterone for schizophrenia</TITLE>
<SUMMARY_BODY>
<P>About 1% of people suffer from schizophrenia, a serious mental illness found in all societies and cultures. Many treatments options are available to reduce the dramatic symptoms of this illness such as the false beliefs (delusions) and false or distorted perceptions (hallucinations). Other symptoms, such as emotional withdrawal and apathy are also often seen with schizophrenia and seem less responsive to treatment with antipsychotic drugs. In addition, some people continue to experience delusions and hallucinations despite adequate use of antipsychotic drugs and often supplementary treatments are used. These supplementary treatments include sex hormones such as estrogen and testosterone. </P>
<P>We reviewed the effects of dehydroepiandrosterone (DHEA)/testosterone as an adjunctive therapy to standard antipsychotic drugs for people with schizophrenia and found three relevant small, short studies. All trials compared antipsychotic drugs plus DHEA with antipsychotic drugs and placebo. Results are inconclusive, with most outcomes being either non-significant or contradictory and a much larger, conclusive study should be undertaken. Currently however, people with schizophrenia should only agree to take this experimental treatment within the context of a well designed experimental study. We found nothing in these studies to suggest that it should be used in routine care.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Recently, sex hormones such as estrogens and testosterone or its derivatives have been the focus of interest for treatment of persistent symptoms associated with schizophrenia.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To review the effects of dehydroepiandrosterone (DHEA)/testosterone as adjunctive therapy to standard antipsychotic drugs.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Schizophrenia Group Trials Register (January 2007).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>We included all clinical randomised trials comparing DHEA/testosterone plus standard antipsychotic treatment with standard treatment alone.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>We independently selected studies and extracted data. For dichotomous data we calculated the relative risk (RR) and its 95% confidence interval (CI) on an intention to treat basis, using a fixed effects model. We presented continuous data using the weighted mean difference statistic, with a 95% confidence interval using a fixed effects model.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>We found three relevant small, short trials (total n=126). Clinical Global Impression data were equivocal (n=27, 1 RCT, WMD -0.43 CI -0.9 to 0.1). Average total PANSS scores were not significantly different between the DHEA plus antipsychotic group and those given antipsychotic drugs and placebo (n=82, 2 RCTs, WMD -4.16 CI -13.8 to 5.5). PANSS positive scores were equivocal (n=55, 1 RCT, WMD -1.00 CI -3.8 to 1.8). For negative symptoms binary SANS scale data favoured the DHEA plus antipsychotic group (n=30, 1 RCT, RR 0.23 CI 0.1 to 0.6, NNT 2 CI 2 to 3) but PANSS negative scores were not significantly different between comparison groups (n=55, 1 RCT, WMD -2.30 CI -6.4 to 1.8). About 17% of people left both groups early (n=64, 2 RCTs, RR 0.80 CI 0.3 to 2.4). St Hans Rating Scale data for extrapyramidal symptoms favoured the DHEA plus antipsychotic group (n=30, 1 RCT, WMD -5.00 CI -8.8 to -1.2) but akathisia ratings were equivocal (n=34, 1 RCT, RR 2.67 CI 0.3 to 23.1). Ratings of parkinsonian movement disorder differed within the same trial depending of the outcome scale used. Quality of life seemed unaffected by use of DHEA (n=55, 1 RCT, WMD 6.20 CI -1.4 to 13.8).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Results are inconclusive with most outcomes being either non-significant or producing contradictory findings. Currently, adjunctive DHEA should remain an experimental treatment for people with schizophrenia.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-05 15:38:53 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Schizophrenia is a serious mental illness found in all societies and cultures with an almost equal incidence and prevalence of approximately 1%. The definite cause or causes of schizophrenia is/are not yet established but abnormalities of several neurotransmitters/neuroreceptors have been implicated. Antipsychotic medication, acting on these neuroreceptors, help most people with schizophrenia attain satisfactory results, especially with regard to the so-called positive symptoms such as delusions, hallucinations and disordered thinking (<LINK REF="REF-Joy-2002" TYPE="REFERENCE">Joy 2002</LINK>, <LINK REF="REF-Thornley-2002" TYPE="REFERENCE">Thornley 2002</LINK>). </P>
<P>For negative symptoms, such as the poor volition and apathy that are often are seen with schizophrenia, results produced by medications are far less evident (<LINK REF="REF-Crow-1980" TYPE="REFERENCE">Crow 1980</LINK>, <LINK REF="REF-Andreasen-1985" TYPE="REFERENCE">Andreasen 1985</LINK>, <LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>). New generation antipsychotic drugs, such as amisulpride, olanzapine or risperidone, were purported to have changed this but the evidence is not convincing (<LINK REF="REF-Duggan-2002" TYPE="REFERENCE">Duggan 2002</LINK>, <LINK REF="REF-Kennedy-2002" TYPE="REFERENCE">Kennedy 2002</LINK>, <LINK REF="REF-Mota-Neto-2002" TYPE="REFERENCE">Mota Neto 2002</LINK>). For some people with schizophrenia, even the positive symptoms seem refractory to drug treatment. The drug clozapine in particular is suggested as a treatment for problematic refractory symptoms. However, clozapine is associated with agranulocytosis and cardiac problems (<LINK REF="REF-Rivaz_x002d_Vasquez-2003" TYPE="REFERENCE">Rivaz-Vasquez 2003</LINK>). Many people with schizophrenia have residual positive or negative symptoms, with figures ranging from 20-50% (<LINK REF="REF-Dilling-2000" TYPE="REFERENCE">Dilling 2000</LINK>). </P>
<P>Supplementary treatments, adjuncts to standard care with antipsychotic medication, have been used to help this group of people. These include the sex hormones such as oestrogen and testosterone. Recent investigations suggest certain abnormalities of serum testosterone levels and its derivative dehydroepiandrosterone (DHEA) in people with schizophrenia. As compared to matched controls, people suffering from schizophrenia exhibit significantly lower serum levels of oestradiol, oestrogen, testosterone and free testosterone and abnormalities in cortisol/DHEA ratio (<LINK REF="REF-Huber-2005" TYPE="REFERENCE">Huber 2005</LINK>, <LINK REF="REF-Taherianfard-2005" TYPE="REFERENCE">Taherianfard 2005</LINK>, <LINK REF="REF-Silver-2005" TYPE="REFERENCE">Silver 2005</LINK>, <LINK REF="REF-Goyal-2004" TYPE="REFERENCE">Goyal 2004</LINK>, <LINK REF="REF-Harris-2001" TYPE="REFERENCE">Harris 2001</LINK>, <LINK REF="REF-Ritsner-2005" TYPE="REFERENCE">Ritsner 2005</LINK>). Recent controlled trials suggest an efficacy of DHEA augmentation for people with schizophrenia displaying negative, depressive and anxiety symptoms (<LINK REF="REF-Strous-2003" TYPE="REFERENCE">Strous 2003</LINK>). There is also one report that suggests that DHEA administration improves extrapyramidal symptoms in schizophrenic patients being treated with antipsychotic drugs (<LINK REF="STD-Nachshoni-2005" TYPE="STUDY">Nachshoni 2005</LINK>). The findings raise important issues regarding the role of neurosteroids in general, and DHEA in particular, in the ongoing pharmacotherapy of schizophrenia. Oestrogen is the focus of another sister review but in this analysis we seek to find and assimilate the current best evidence for the value of testosterone or its derivatives for treating people with schizophrenia. </P>
<P>Technical background<BR/>Dehydroepiandrosterone (DHEA) is a steroid produced by adrenal glands. It is secreted in small amounts by the testis and ovaries and can be converted into testosterone. DHEA is available in the USA as over the counter medication in 50 mg and 100 mg tablets.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To review the effects of dehydroepiandrosterone (DHEA)/testosterone as an adjunctive therapy to standard antipsychotic drugs.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-05 15:38:53 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-11-05 15:37:52 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>We included all relevant randomised controlled trials. Where a trial was described as 'double-blind', but it was implied that the study was randomised, we included the trial in a sensitivity analysis. If there was no substantive difference within primary outcomes (see 'types of outcome measures') when these 'implied randomisation' studies were added, then we included these in the final analysis. If there was a substantive difference, we only analysed clearly randomised trials and described the results of the sensitivity analysis in the text. We excluded quasi-randomised studies, such as those allocating by alternate days of the week.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>We included people with schizophrenia defined and diagnosed by the authors of the original studies by any criteria.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>1. Treatment with antipsychotic drugs plus DHEA: any dose and route of administration. <BR/>2. Treatment with antipsychotic drugs plus any other form of testosterone: any dose and route of administration. <BR/>3. Treatment with antipsychotic medication +/- placebo: any dose and route of administration.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-11-05 15:37:52 +0000" MODIFIED_BY="[Empty name]">
<P>We grouped outcomes into short term (up to 12 weeks), medium term (13 to 26 weeks) and long term (over 26 weeks).</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-11-05 15:22:53 +0000" MODIFIED_BY="[Empty name]">
<P>We selected relapse (as defined in the individual studies) as the primary outcome measure but also highlighted adverse effects as being of particular interest.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-11-05 15:37:52 +0000" MODIFIED_BY="[Empty name]">
<P>1. Death - suicide and natural causes</P>
<P>2. Global state<BR/>2.1 Healthy days<BR/>2.2 No clinically important change in global state (as defined by individual studies)<BR/>2.3 Average endpoint global state score<BR/>2.4 Average change in global state scores</P>
<P>3. Service outcomes<BR/>3.1 Hospitalisation<BR/>3.2 Time to hospitalisation</P>
<P>4. Mental state (with particular reference to the positive and negative symptoms of schizophrenia)<BR/>4.1 No clinically important change in general mental state<BR/>4.2 Average endpoint general mental state score<BR/>4.3 Average change in general mental state scores<BR/>4.4 No clinically important change in specific symptoms (positive symptoms of schizophrenia, negative symptoms of schizophrenia, depression, mania)<BR/>4.5 Average endpoint specific symptom score<BR/>4.6 Average change in specific symptom scores</P>
<P>5. General functioning<BR/>5.1 No clinically important change in general functioning<BR/>5.2 Average endpoint general functioning score<BR/>5.3 Average change in general functioning scores<BR/>5.4 No clinically important change in specific aspects of functioning, such as social or life skills<BR/>5.5 Average endpoint specific aspects of functioning, such as social or life skills<BR/>5.6 Average change in specific aspects of functioning, such as social or life skills</P>
<P>6. Behaviour<BR/>6.1 No clinically important change in general behaviour<BR/>6.2 Average endpoint general behaviour score<BR/>6.3 Average change in general behaviour scores<BR/>6.4 No clinically important change in specific aspects of behaviour<BR/>6.5 Average endpoint specific aspects of behaviour<BR/>6.6 Average change in specific aspects of behaviour</P>
<P>7. Adverse effects - general and specific<BR/>7.1 Average endpoint general adverse effect score<BR/>7.2 Average change in general adverse effect scores<BR/>7.3 Clinically important specific adverse effects<BR/>7.4 Average endpoint specific adverse effects<BR/>7.5 Average change in specific adverse effects</P>
<P>8. Engagement with services</P>
<P>9. Satisfaction with treatment<BR/>9.1 Leaving the studies early<BR/>9.2 Recipient of care not satisfied with treatment<BR/>9.3 Recipient of care average satisfaction score<BR/>9.4 Recipient of care average change in satisfaction scores<BR/>9.5 Carer not satisfied with treatment<BR/>9.6 Carer average satisfaction score<BR/>9.7 Carer average change in satisfaction scores</P>
<P>10. Quality of life<BR/>10.1 No clinically important change in quality of life<BR/>10.2 Average endpoint quality of life score<BR/>10.3 Average change in quality of life scores<BR/>10.4 No clinically important change in specific aspects of quality of life<BR/>10.5 Average endpoint specific aspects of quality of life<BR/>10.6 Average change in specific aspects of quality of life</P>
<P>11. Economic outcomes<BR/>11.1 Direct costs<BR/>11.2 Indirect costs</P>
<P>12. Cognitive functioning<BR/>12.1 No clinically important change in cognitive functioning<BR/>12.2 Average endpoint cognitive functioning score<BR/>12.3 Average change in cognitive functioning scores<BR/>12.4 No clinically important change in specific aspects of cognitive functioning<BR/>12.5 Average endpoint specific aspects of cognitive functioning<BR/>12.6 Average change in specific aspects of cognitive functioning</P>
<P>13. Leaving the study early</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-11-05 15:38:53 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2008-11-05 15:38:24 +0000" MODIFIED_BY="[Empty name]">
<P>We searched The Cochrane Schizophrenia Group Trials Register (January 2007) using the phrase:</P>
<P>[((*androsten* or dehydroepiand* or dehydroisoand* or DHEA* or prasteron* or testoster*) in title, abstract and index fields in REFERENCE) OR ((dehydroepiandrosterone or testosterone) in interventions field in STUDY]<BR/>This register is compiled by systematic searches of major databases, hand searches and conference proceedings (see Group Module).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-11-05 15:38:53 +0000" MODIFIED_BY="[Empty name]">
<P>1. Reference lists<BR/>We inspected all references of articles selected for inclusion for further relevant trials.</P>
<P>2. Personal contact<BR/>We contacted the first author of each included study for information regarding unpublished trials.</P>
<P>3. The US Food and Drugs Administration website - http://www.fda.gov.<BR/>We searched this site using the phrase '*DHEA* or *dehydroepiandrosterone*.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>[For definitions of terms used in this and other sections, please refer to the Glossary] </P>
<P>1. Study selection <BR/>We (AE, AK) independently inspected and selected all abstracts identified by the search. Where disagreement occurred we resolved this by discussion, or when doubt remained, we obtained the full article for further inspection. If disagreement remained, we added the article to the list of those awaiting assessment and contacted the study authors for clarification.</P>
<P>2. Quality assessment <BR/>We assessed methodological quality of included trials using the criteria described in the Cochrane Handbook (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>). This simple set of criteria is based on the evidence of a strong association between overestimation of effect and poor concealment of allocation (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>) and is defined as follows:</P>
<P>A. Low risk of bias (adequate allocation concealment)<BR/>B. Moderate risk of bias (some doubt about the results)<BR/>C. High risk of bias (inadequate allocation concealment)</P>
<P>For the purpose of the analysis in this review, trials had to meet criterion A or B of the handbook. We excluded trials not described as randomised by the authors, and with no implication of randomisation, and rated these as category C.</P>
<P>3. Data extraction <BR/>We (AE, AK) independently extracted data from selected trials. Where disagreement occurred, we attempted resolution by discussion. If doubt remained and further information was needed to resolve the dilemma, we did not enter data, but contacted authors' of the studies for clarification. </P>
<P>4. Data management<BR/>4.1 Intention to treat<BR/>For studies that do not specify the reasons for persons leaving the study early (dropping out), we assumed that these people had no change in their clinical outcome variables. A problem with increasing drop-out rates in randomised trials on drug treatments for schizophrenia has been reported (<LINK REF="REF-Wahlbeck-2001" TYPE="REFERENCE">Wahlbeck 2001</LINK>). Since there is no evidence as to what degree of attrition makes a reasonable analysis of the data impossible, all trials were eligible to be included in the main analysis. We did not include outcomes if more than 40% of people were not reported in the final analysis. We tested, where possible, whether exclusion of outcomes with drop-out rates higher than 40% significantly changed results of the primary outcomes in a sensitivity analysis. When insufficient data were provided to identify the original group size (prior to people leaving or being withdrawn from the study), we contacted trial authors and, in the interim we assigned those trials to those 'awaiting assessment'. </P>
<P>4.2 Crossover design<BR/>We expected that some trials would use a crossover design and, in order to exclude the potential additive effect on these trials in the second or subsequent stages, only data from the first stage were to have been used.</P>
<P>4.3 Data types<BR/>Outcomes are assessed using continuous measures (for example changes on a behaviour scale), categorical measures (for example, one of three categories on a behaviour scale, such as 'little change', 'moderate change' or 'much change') or dichotomous measures (for example, either 'no important changes' or 'important changes' in a person's behaviour). Currently RevMan does not support data from more than two categories, so these data would only have been presented in a table and not analysed.</P>
<P>4.3.1 Dichotomous data: Where possible, we made efforts to convert outcome measures to dichotomous data. This may be done by identifying cut off points on rating scales and dividing people accordingly into 'clinically improved' or 'not clinically improved'. If authors of a study had used a predefined cut off point for determining clinical effectiveness we accepted this. Otherwise it was generally assumed that a 50% reduction of a scale (e.g. the Brief Psychiatric Rating Scale - <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) or a rating of 'at least much improved' according to the Clinical Global Impression Scale (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>) could be considered as a clinically significant response (<LINK REF="REF-Leucht-2005a" TYPE="REFERENCE">Leucht 2005a</LINK>, <LINK REF="REF-Leucht-2005b" TYPE="REFERENCE">Leucht 2005b</LINK>). </P>
<P>For dichotomous outcomes, we estimated a relative risk (RR) with the 95% confidence interval (CI) based on a fixed effects model. It has been shown that RR is more intuitive (<LINK REF="REF-Boissel-1999" TYPE="REFERENCE">Boissel 1999</LINK>) than odds ratios and that odds ratios tend to be interpreted as RR by clinicians (<LINK REF="REF-Deeks-2000" TYPE="REFERENCE">Deeks 2000</LINK>). This misinterpretation then leads to an overestimate of the effect. When data were statistically significant we calculated the Number Needed to Treat (NNT) and/or the Number Needed to Harm (NNH) as the inverse of the risk reduction.</P>
<P>4.3.2 Continuous data<BR/>Continuous data on outcomes in trials relevant to mental health issues are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data we applied the following standards to continuous final value endpoint data before inclusion: (a) standard deviations and means were reported in the paper or were obtainable from the authors; (b) when a scale started from zero, the standard deviation, when multiplied by two, should be less than the mean (otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution - <LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>); In cases with data that are greater than the mean they were entered into 'Other data' table as skewed data. If a scale starts from a positive value (such as PANSS, which can have values from 30 to 210) the calculation described above in (b) should be modified to take the scale starting point into account. In these cases skewness is present if 2SD&gt;(S-Smin), where S is the mean score and Smin is the minimum score.</P>
<P>For change data (mean change from baseline on a rating scale) it is impossible to tell whether data are non-normally distributed (skewed) or not, unless individual patient data are available. After consulting the ALLSTAT electronic statistics mailing list, we presented change data in RevMan graphs to summarise available information. In doing this, we assumed either that data were not skewed or that the analysis could cope with the unknown degree of skew. </P>
<P>4.3.3 Final endpoint value versus change data<BR/>Where both final endpoint data and change data were available for the same outcome category, we only presented final endpoint data. We acknowledge that by doing this much of the published change data may be excluded, but argue that endpoint data is more clinically relevant and that if change data were to be presented along with endpoint data, it would be given undeserved equal prominence. We are contacting authors of studies reporting only change data for endpoint figures. </P>
<P>4.3.4 Summary statistics: for continuous outcomes, we estimated a weighted mean difference (WMD) between groups, again, using a fixed effects model. Whenever possible we took the opportunity to make direct comparisons between trials that had used the same measurement instrument to quantify specific outcomes. Where continuous data were presented from different scales rating the same effect, we presented the data but did not attempt synthesis. Intention-to-treat versus completer analyses: in the case of continuous data we assumed that often an intention-to-treat analysis was not possible so we analysed data as they were presented in the original publications. </P>
<P>4.4 Rating scales<BR/>A wide range of instruments are available to measure mental health outcomes. These instruments vary in quality and many are not valid, and are known to be subject to bias in trials of treatments for schizophrenia (<LINK REF="REF-Marshall-2000" TYPE="REFERENCE">Marshall 2000</LINK>). Therefore we only included continuous data from rating scales if the measuring instrument had been described in a peer-reviewed journal.</P>
<P>4.5 Cluster trials<BR/>Studies increasingly employ "cluster randomisation" (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra class correlation in clustered studies, leading to a "unit of analysis" error (<LINK REF="REF-Divine-1992" TYPE="REFERENCE">Divine 1992</LINK>) whereby p values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type 1 errors (<LINK REF="REF-Bland-1997" TYPE="REFERENCE">Bland 1997</LINK>, <LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>).</P>
<P>Should clustering have not been accounted for in primary studies, we would have presented the data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error in subsequent versions of this review we would have not sought to contact first authors of studies to obtain intra-class correlation co-efficients of their clustered data and to adjust for this using accepted methods (<LINK REF="REF-Gulliford-1999" TYPE="REFERENCE">Gulliford 1999</LINK>). Where clustering could have been incorporated into the analysis of primary studies, we would have also presented these data as if from a non-cluster randomised study, but adjusted for the clustering effect.</P>
<P>We would have sought statistical advice and would have been advised that the binary data as presented in a report should have been divided by a "design effect". This would have been calculated using the mean number of participants per cluster (m) and the intraclass correlation co-efficient (ICC) [Design effect=1+(m-1)*ICC] (<LINK REF="REF-Donner-2002" TYPE="REFERENCE">Donner 2002</LINK>). If the ICC would not have been reported it would have assumed to be 0.1 (<LINK REF="REF-Ukoumunne-1999" TYPE="REFERENCE">Ukoumunne 1999</LINK>).<BR/> <BR/>If cluster studies had been appropriately analysed taking into account intra-class correlation coefficients and relevant data documented in the report, synthesis with other studies would have been possible using the generic inverse variance technique.</P>
<P>5. Heterogeneity<BR/>First of all, we considered all included studies within any comparison to estimate clinical heterogeneity. Then we visually inspected graphs to investigate the possibility of statistical heterogeneity. We supplemented this, with, primarily, the I-squared statistic. This provides an estimate of the percentage of inconsistency thought to be due to chance. Where the I-squared estimate was greater than or equal to 75% we interpreted this as evidence of high levels of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). On such occasions, reasons for heterogeneity were sought, and if we found any clear reasons, we excluded studies contributing to the heterogeneity and presented their results separately. If we found no clear reasons we presented all data together and commented on the heterogeneity within the discussion. </P>
<P>6. Publication bias <BR/>Data from all included trials were entered into a funnel graph (trial effect versus trial size or 'precision') in an attempt to investigate overt small study bias. We did not undertake a formal test of funnel plot asymmetry (suggesting potential publication bias).</P>
<P>7. Sensitivity analysis<BR/>We hoped to examine whether exclusion of trials with attrition rates higher than 40% led to a significant change in the primary outcomes.</P>
<P>8. General <BR/>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for DHEA/testosterone.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>For substantive descriptions of the studies, please see Included and Excluded Studies tables. </P>
<P>1. Excluded studies<BR/>We excluded 15 studies. Two of these were not randomised (<LINK REF="STD-Shen-2001" TYPE="STUDY">Shen 2001</LINK>, <LINK REF="STD-Song-2002" TYPE="STUDY">Song 2002</LINK>), and another two because they involved healthy volunteers (<LINK REF="STD-Ishigooka-1991" TYPE="STUDY">Ishigooka 1991</LINK>, <LINK REF="STD-von-Bahr-1991" TYPE="STUDY">von Bahr 1991</LINK>). We excluded eight studies because they did not use either DHEA or any other form of testosterone (<LINK REF="STD-Brambilla-1979" TYPE="STUDY">Brambilla 1979</LINK>, <LINK REF="STD-Cotes-1978" TYPE="STUDY">Cotes 1978</LINK>, <LINK REF="STD-Kinon-2006" TYPE="STUDY">Kinon 2006</LINK>, <LINK REF="STD-Knegtering-2004" TYPE="STUDY">Knegtering 2004</LINK>, <LINK REF="STD-Kulkarni-2002" TYPE="STUDY">Kulkarni 2002</LINK>, <LINK REF="STD-Kulkarni-2005" TYPE="STUDY">Kulkarni 2005</LINK>, <LINK REF="STD-Poyurovsky-2003" TYPE="STUDY">Poyurovsky 2003</LINK>, <LINK REF="STD-Rinieris-1988" TYPE="STUDY">Rinieris 1988</LINK>). Another study, <LINK REF="STD-Sackler-1951" TYPE="STUDY">Sackler 1951</LINK>, used different doses of testosterone and oestradiol but there was no concomitant use of antipsychotic medication as required by the protocol. <LINK REF="STD-Ko-2006" TYPE="STUDY">Ko 2006</LINK> and <LINK REF="STD-Strous-2006" TYPE="STUDY">Strous 2006</LINK> did seem relevant but reported no usable data.</P>
<P>2. Awaiting assessment<BR/>No studies are awaiting assessment. </P>
<P>3. Ongoing studies<BR/>We did not identify any ongoing trials.</P>
<P>4. Included studies<BR/>We identified three studies (six reports) that could be included. All three were described as randomised. <LINK REF="STD-Ritsner-2006" TYPE="STUDY">Ritsner 2006</LINK> was a crossover trial. All three studies were also stated to be double blind.</P>
<P>4.1 Length of trials<BR/>All studies reported data for short-term follow-up (up to 12 weeks).</P>
<P>4.2 Participants<BR/>In total 126 people were involved in these trials, all of them comparing antipsychotic drugs and DHEA versus antipsychotic drugs and placebo. <LINK REF="STD-Strous-2002" TYPE="STUDY">Strous 2002</LINK> included people with a diagnosis of schizophrenia. <LINK REF="STD-Nachshoni-2005" TYPE="STUDY">Nachshoni 2005</LINK> and <LINK REF="STD-Ritsner-2006" TYPE="STUDY">Ritsner 2006</LINK> included people with the diagnosis of either schizophrenia or schizoaffective disorder. All three trials used DSM-IV as operational diagnostic criteria. There were more men in these studies than women (81 men vs 35 women). <LINK REF="STD-Ritsner-2006" TYPE="STUDY">Ritsner 2006</LINK> and <LINK REF="STD-Strous-2002" TYPE="STUDY">Strous 2002</LINK> did not specify sex distribution of seven and three participants respectively. The age ranges across studies were between 19-64 years. None of the three studies described participant's severity of illness. </P>
<P>4.3 Setting<BR/>All studies were undertaken in Israel. <LINK REF="STD-Nachshoni-2005" TYPE="STUDY">Nachshoni 2005</LINK> and <LINK REF="STD-Strous-2002" TYPE="STUDY">Strous 2002</LINK> were described as taking place in inpatient settings, whilst <LINK REF="STD-Ritsner-2006" TYPE="STUDY">Ritsner 2006</LINK> used both inpatient and outpatient settings.</P>
<P>4.4 Study size<BR/>
<LINK REF="STD-Ritsner-2006" TYPE="STUDY">Ritsner 2006</LINK> is the largest study with 62 people and <LINK REF="STD-Nachshoni-2005" TYPE="STUDY">Nachshoni 2005</LINK> 34, and <LINK REF="STD-Strous-2002" TYPE="STUDY">Strous 2002</LINK> only 30.</P>
<P>4.5 Interventions<BR/>The trialists administered DHEA in range of doses from 25 mg to 200 mg per day. None of the studies gave dose ranges for the antipsychotic drugs used. <LINK REF="STD-Strous-2002" TYPE="STUDY">Strous 2002</LINK> mentioned that haloperidol, fluphenazine, zuclopenthixol, risperidone, olanzapine and clozapine were used. </P>
<P>4.6 Outcomes<BR/>Despite having been undertaken in the same country and within a few years of each other, all three trials used several scales, but there did not seem to be much co-ordination of effort. <LINK REF="STD-Strous-2002" TYPE="STUDY">Strous 2002</LINK> for example, reported on global outcomes using several scales (CGI, PANSS, SANS, HAM-A, HAM-D) to measure global clinical improvement in the short term. On the other hand, <LINK REF="STD-Ritsner-2006" TYPE="STUDY">Ritsner 2006</LINK> used PANSS, ESRS, AIMS and Quality of Life scale. <LINK REF="STD-Nachshoni-2005" TYPE="STUDY">Nachshoni 2005</LINK> used BPRS scale to measure mental state. Data were reported as continuous. All three studies reported usable data on adverse effects. Both <LINK REF="STD-Nachshoni-2005" TYPE="STUDY">Nachshoni 2005</LINK> and <LINK REF="STD-Strous-2002" TYPE="STUDY">Strous 2002</LINK> reported usable data on participants leaving the study early.</P>
<P>4.6.1 Outcome scales: details of only the scales that provided usable data are shown below. Reasons for exclusions of data are given under 'Outcomes' in the 'Included studies' section. </P>
<P>4.6.1.1 Global state <BR/>4.6.1.1.1 Clinical Global Impression Scale - CGI Scale (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>) <BR/>Trialists used this to assess both severity of illness and clinical improvement. The CGI is a seven-point scoring system is usually used with low scores showing decreased severity and/or overall improvement. <LINK REF="STD-Nachshoni-2005" TYPE="STUDY">Nachshoni 2005</LINK> and <LINK REF="STD-Strous-2002" TYPE="STUDY">Strous 2002</LINK> reported data from this scale for both severity of illness and improvement subscales.</P>
<P>4.6.1.2 Mental state scales<BR/>4.6.1.2.1 Brief Psychiatric Rating Scale - BPRS (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>)<BR/>This is used to assess the severity of abnormal mental state. The original scale has 16 items, but a revised 18-item scale is commonly used. Each item is defined on a seven-point scale varying from 'not present' to 'extremely severe', scoring from 0-6 or 1-7. Scores can range from 0-126, with high scores indicating more severe symptoms. <LINK REF="STD-Nachshoni-2005" TYPE="STUDY">Nachshoni 2005</LINK> reported data from this scale.</P>
<P>4.6.1.2.2 Positive and Negative Syndrome Scale - PANSS (<LINK REF="REF-Kay-1987" TYPE="REFERENCE">Kay 1987</LINK>)<BR/>This schizophrenia scale has 30 items, each of which can be defined on a seven-point scoring system varying from 1 - absent to 7 - extreme. This scale can be divided into 3 sub-scales for measuring the severity of general psychopathology, positive symptoms (PANSS-P), and negative symptoms (PANSS-N). A low score indicates lesser severity. <LINK REF="STD-Ritsner-2006" TYPE="STUDY">Ritsner 2006</LINK> and <LINK REF="STD-Strous-2002" TYPE="STUDY">Strous 2002</LINK> reported data from this scale. </P>
<P>4.6.1.3 Adverse effects scales<BR/>4.6.1.3.1 Extrapyramidal Symptom Rating Scale - ESRS (<LINK REF="REF-Chouinard-1980" TYPE="REFERENCE">Chouinard 1980</LINK>)<BR/>This consists of a questionnaire relating to parkinsonian symptoms (nine items), a physician's examination for parkinsonism and dyskinetic movements (eight items), and a clinical global impression of tardive dyskinesia. <LINK REF="STD-Ritsner-2006" TYPE="STUDY">Ritsner 2006</LINK> reported data from this scale.</P>
<P>4.6.1.3.2 UKU Side Effects Rating Scale - UKU-SERS (<LINK REF="REF-Lingjaerde-1987" TYPE="REFERENCE">Lingjaerde 1987</LINK>)<BR/>The UKU rates four major topics: psychological adverse effects (10 items), neurological adverse effects (8 items), autonomic adverse effects (11 items) and other adverse effects (19 items). Each item is defined by means of a four-point scale where zero means-not or doubtfully present. Scoring range is 0-144. <LINK REF="STD-Nachshoni-2005" TYPE="STUDY">Nachshoni 2005</LINK> reported data from this scale.</P>
<P>4.6.1.3.3 The Sanct Hans rating scale - SHRS (<LINK REF="REF-Gerlach-1993" TYPE="REFERENCE">Gerlach 1993</LINK>)<BR/>The St. Hans Rating Scale (SHRS) is a multidimensional rating scale for the evaluation of neuroleptic-induced hyperkinesia, parkinsonism, akathisia and dystonia. <LINK REF="STD-Nachshoni-2005" TYPE="STUDY">Nachshoni 2005</LINK> reported data from this scale.</P>
<P>4.6.1.3.4 Abnormal Involuntary Movement Scale - AIMS (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>) <BR/>The Abnormal Involuntary Movement Scale has been used to assess abnormal involuntary movements associated with antipsychotic drugs, such as tardive dyskinesia and chronic akathisia, as well as 'spontaneous' motor disturbance related to the illness itself. Tardive dyskinesia is a long-term, drug-induced movement disorder. However, using this scale in short-term trials may also be helpful to assess some rapidly occurring abnormal movement disorders such as tremor. Scoring consists of rating movement severity in the anatomical areas (facial/oral, extremities, and trunk) on a five point scale (0-4). A low score indicates low levels of dyskinetic movements. <LINK REF="STD-Ritsner-2006" TYPE="STUDY">Ritsner 2006</LINK> reported data from this scale.</P>
<P>4.6.2 Redundant data<BR/>Enormous efforts were invested in studies rating and recording data that are then reported in such a way as to render them of no use to reviews such as this. Trialists often report continuous measures of global, or mental state but without any variances.</P>
<P>4.6.3 Missing outcomes<BR/>We found no usable outcomes for the following categories: service outcomes, engagement with services and satisfaction with treatment. It is possible that there is a systematic bias in which data, such as the simple binary outcome of death, are not reported consistently or well.</P>
<P>4.6.4 Primary outcomes<BR/>Not one study reported our pre-stated primary outcome of relapse. All other outcomes in this review were felt at the time of writing the protocol, to be of secondary importance but we recognise that they may be of primary interest to others.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Three studies met the inclusion criteria for this review. </P>
<P>1. Randomisation<BR/>All three included studies were described as randomised. <LINK REF="STD-Nachshoni-2005" TYPE="STUDY">Nachshoni 2005</LINK> and <LINK REF="STD-Strous-2002" TYPE="STUDY">Strous 2002</LINK> reported using "random number generation". None of the studies stated how allocation concealment was conducted or ensured.</P>
<P>2. Blinding<BR/>All the included studies were described as "double blind" but further information on blindness of raters was not available in any trial. </P>
<P>3. Leaving the study early<BR/>Four participants in <LINK REF="STD-Nachshoni-2005" TYPE="STUDY">Nachshoni 2005</LINK> failed to complete the study. Similarly seven patients were withdrawn from <LINK REF="STD-Strous-2002" TYPE="STUDY">Strous 2002</LINK>. The reasons for leaving the studies early are inadequately reported. The studies also did not clearly describe how they used data for people who were lost to follow up. We found no reporting of attempts to validate any assumptions by following up those who dropped out early.</P>
<P>4. Data reporting<BR/>Overall, due to poor reporting we were unable to use all outcome data. Findings presented as graphs, whether as percentiles or as inexact p-values, are often of little use to a reviewer. Studies sometimes failed to provide standard deviations when reporting mean changes. We are seeking further data from the first authors of relevant trials.</P>
<P>4.1 Outcome measures.<BR/>They varied considerably across the studies. One study assessed Clinical Global Impression (both severity and improvement) (<LINK REF="STD-Strous-2002" TYPE="STUDY">Strous 2002</LINK>). For assessment of symptoms of schizophrenia PANSS was the most common instrument that was used (<LINK REF="STD-Ritsner-2006" TYPE="STUDY">Ritsner 2006</LINK>, <LINK REF="STD-Strous-2002" TYPE="STUDY">Strous 2002</LINK>) but <LINK REF="STD-Nachshoni-2005" TYPE="STUDY">Nachshoni 2005</LINK> used BPRS for the same purpose. <LINK REF="STD-Strous-2002" TYPE="STUDY">Strous 2002</LINK> assessed negative symptoms of schizophrenia with SANS and depressive symptoms by HAM-D and anxiety symptoms by HAM-A. Two studies reported data on leaving the study early and the reasons for it (<LINK REF="STD-Nachshoni-2005" TYPE="STUDY">Nachshoni 2005</LINK>, <LINK REF="STD-Strous-2002" TYPE="STUDY">Strous 2002</LINK>). All three studies assessed adverse effects due to antipsychotic treatment. However the instruments varied from study to study. They included UKU scale for the side effect profile and St Hans Rating Scale for extrapyramidal symptoms (SHRS) (<LINK REF="STD-Nachshoni-2005" TYPE="STUDY">Nachshoni 2005</LINK>), Extrapyramidal Symptom Rating Scale (ESRS) and AIMS (<LINK REF="STD-Ritsner-2006" TYPE="STUDY">Ritsner 2006</LINK>). Quality of life was examined in one study by the use of Quality of Life Scale and self reported QOL and Satisfaction Questionnaire (<LINK REF="STD-Ritsner-2006" TYPE="STUDY">Ritsner 2006</LINK>).</P>
<P>5. Overall<BR/>All three studies were categorised as being prone to at least a moderate degree of bias due to the poor reporting of allocation concealment at the point of randomisation.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>1. The search<BR/>We identified 21 citations from the search strategy, six of which were relevant to the three trials we could include.<BR/> <BR/>2. COMPARISON: DHEA + ANTIPSYCHOTIC versus PLACEBO + ANTIPSYCHOTIC (only short term)</P>
<P>2.1 Global state<BR/>We found continuous Clinical Global Impression scale data (<LINK REF="STD-Strous-2002" TYPE="STUDY">Strous 2002</LINK>) were equivocal for the outcomes of 'improvement' (n=27, WMD -0.43 CI -0.9 to 0.1) and 'severity of illness' (n=27, WMD -0.33 CI -0.9 to 0.3) between those given the DHEA antipsychotic combination and the control group given antipsychotic and placebo. No other global state data were available for analyses.</P>
<P>2.2 Mental state<BR/>2.2.1 General<BR/>We found average total PANSS data were not significantly different between the DHEA plus antipsychotic group (n=82, 2 RCTs, WMD -4.16 CI -13.8 to 5.5) and those given antipsychotic drugs and placebo. Similarly we found BPRS total endpoint scores were not significantly different between treatment groups (<LINK REF="STD-Nachshoni-2005" TYPE="STUDY">Nachshoni 2005</LINK>, n=30, WMD -1.20 CI -8.8 to 6.4).</P>
<P>2.2.2 Specific symptoms<BR/>PANSS positive scores were equivocal (1 RCT, n=55, WMD -1.00 CI -3.8 to 1.8). For negative symptoms we found more data. Dichotomised SANS scale data from one small study (n=30) did favour the DHEA plus antipsychotic group compared with the antipsychotic plus placebo group (RR 0.23 CI 0.1 to 0.6, NNT 2 CI 2 to 3). PANSS negative scores, however, were not significantly different between comparison groups (1 RCT, n=55, WMD -2.30 CI -6.4 to 1.8). </P>
<P>Authors of <LINK REF="STD-Strous-2002" TYPE="STUDY">Strous 2002</LINK> kindly supplied scale-derived pre-crossover data for depression and anxiety scores. Standard deviations are wide, indicating skewed data, so we included these in 'other data tables'. There are no clear differences between groups.</P>
<P>2.3 Leaving the study early<BR/>The number of people leaving the study early for any reason were not significantly different between treatment groups (2 RCTs, n=64, RR 0.80 CI 0.3 to 2.4). One of the studies reported attrition due to uncooperativeness or getting worse (<LINK REF="STD-Strous-2002" TYPE="STUDY">Strous 2002</LINK>, n=30, RR 0.20 CI 0.03 to 1.5).</P>
<P>2.4 Adverse events<BR/>2.4.1 General movement disorders<BR/>We found general movement disorders reported by <LINK REF="STD-Nachshoni-2005" TYPE="STUDY">Nachshoni 2005</LINK> using St Hans rating scale for extrapyramidal side effects favoured the DHEA plus antipsychotic group (n=30, WMD -5.00 CI -8.8 to -1.2) compared with the antipsychotic plus placebo group. <LINK REF="STD-Ritsner-2006" TYPE="STUDY">Ritsner 2006</LINK> reported movement disorders by Abnormal Involuntary Movements and Extrapyramidal Symptom Rating Scales. These data were reported under 'other data' table as variances were very wide. Nevertheless they show no difference between two treatment groups.</P>
<P>2.4.2 Specific movement disorders<BR/>2.4.2.1 Akathisia<BR/>We found no statistically significant differences between the DHEA plus antipsychotic group and those given antipsychotic and placebo (<LINK REF="STD-Nachshoni-2005" TYPE="STUDY">Nachshoni 2005</LINK>, n=34, RR 2.67 CI 0.3 to 23.1). Continuous data reported by <LINK REF="STD-Nachshoni-2005" TYPE="STUDY">Nachshoni 2005</LINK> were too skewed to present graphically, although they did not indicate any difference between groups.</P>
<P>2.4.2.2 Parkinsonism<BR/>We found no significant difference for the occurrence of parkinsonian movement disorder between treatment groups (<LINK REF="STD-Nachshoni-2005" TYPE="STUDY">Nachshoni 2005</LINK>, n=34, RR 2.67 CI 0.3 to 23.1) when measured using the Sanct Hans Rating Scale. However, <LINK REF="STD-Nachshoni-2005" TYPE="STUDY">Nachshoni 2005</LINK> also used the UKU side effects rating scale, and we found measures of parkinsonism were significantly lower in the DHEA and antipsychotic group (n=30, WMD -4.00 CI -7.5 to -0.6). </P>
<P>2.5 Quality of life<BR/>
<LINK REF="STD-Ritsner-2006" TYPE="STUDY">Ritsner 2006</LINK> (n=55) reported continuous data for the outcome observer rated (n=55, WMD 6.20 CI -1.4 to 13.8) and self reported quality of life scale (n=55, WMD 0.20 CI -0.2 to 0.6) but we found no statistically significant differences between groups.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>1. The studies<BR/>Given the therapeutic interest in androgens as a treatment strategy for schizophrenia is quite recent, the number of studies is limited. It appears that almost all of these studies have been reported from the same centre and by mostly by the same authors. We realise that this is a new area and there may be a process of evolution of the best way of undertaking trials and measuring outcomes, but it was disappointing that the methods, especially the outcome scales, were not more consistent. </P>
<P>1.1 Applicability of findings<BR/>All three studies were conducted in Israel. It is even feasible that participants of these trials were the same.<BR/>All trials involved participants with little in the way of physical and psychiatric co-morbidity and with well-defined schizophrenia or schizoaffective disorder. Such people are important but are a minority in everyday care, where the norm is to find people who suffer from less well defined illnesses combined with problems such as depression and substance misuse. This does not mean that the data are impossible to apply to routine care but just that the differences between the trial populations and those seen in everyday practice should be acknowledged and the implications of those differences on outcomes considered. </P>
<P>1.2 Limited data, confusing data<BR/>All included studies reported data only for the short term (less than 12 weeks) but even then, the collection and quality of the data reported was variable. For example, often mean figures were reported without variances and in this way it was difficult to even present the data. Outcomes were commonly reported using graphs and p-values instead of tables and confidence intervals. The excessive use of graphs did not allow us to acquire sufficient numbers to calculate many measures of effectiveness. </P>
<P>Among the 13 groups of defined outcomes in our protocol, only five were addressed by the studies. We found no data on relapse, hospital and services outcomes, engagement with services, satisfaction with treatment and economic outcomes. There was a lack of information on outcomes that are clinically important such as death, general functioning, behaviour, treatment and hospitalisation. </P>
<P>1.3 Quality of studies<BR/>We appreciate that studies in this population group bring unique difficulties. However there were important methodological difficulties with the trials and therefore any conclusions must be viewed with caution.</P>
<P>2. COMPARISON: DHEA + ANTIPSYCHOTIC versus PLACEBO + ANTIPSYCHOTIC (only short term)</P>
<P>The overall results after DHEA administration are variable depending upon the particular outcome studied.</P>
<P>2.1 Global and mental state <BR/>We were only able to report Clinical Global Impression (CGI) data (<LINK REF="STD-Strous-2002" TYPE="STUDY">Strous 2002</LINK>), from a single study with a sample of just 27 of the 30 participants. The results were non-significant and gave no impression that they were likely to reach statistical significance with a larger sample.</P>
<P>More results were available for mental state, but this was again hampered by small sample sizes. The negative symptom score assessed from the SANS scale produced a large treatment effect, (NNT) of only two. This finding was not supported however, when negative symptoms were assessed using the PANSS negative symptom score. Other mental state measures, PANSS total, PANSS positive and BPRS total were not significantly different. </P>
<P>Overall, these limited results are insufficient to enable us to make any firm conclusions.</P>
<P>2.2 Leaving the study early<BR/>Study attrition from two trials (n=64) did not reveal that DHEA plus antipsychotic treatment was either more or less acceptable to participants than antipsychotic drugs alone. When attrition was categorised due to uncooperativeness or not improving this also revealed no significant differences. Until larger studies are conducted we cannot know if this outcome is reliable.</P>
<P>2.3 Adverse effects<BR/>These outcomes were also inconclusive. General movement disorders, as reported by <LINK REF="STD-Nachshoni-2005" TYPE="STUDY">Nachshoni 2005</LINK> (n=30) favoured the DHEA plus antipsychotic group but with such limited numbers of participants more robust data are needed. Parkinsonism measured by two different scales show contradictory results. The dichotomous data measured by St. Hans Rating Scale revealed no statistically significant difference between treatment groups. However, continuous data for the same outcome recorded using UKU side effects rating scale did favour the concomitant use of DHEA with antipsychotic drugs. When it came to specific symptoms such as akathisia, no significant differences were found. Other ratings of adverse effects reported by <LINK REF="STD-Nachshoni-2005" TYPE="STUDY">Nachshoni 2005</LINK> and <LINK REF="STD-Ritsner-2006" TYPE="STUDY">Ritsner 2006</LINK> were skewed and problematic to interpret. </P>
<P>2.4 Quality of life<BR/>Only <LINK REF="STD-Ritsner-2006" TYPE="STUDY">Ritsner 2006</LINK> reported continuous data for the outcome of observer-rated and self-reported quality of life scale but did not show any difference between DHEA and placebo groups. Use of DHEA does not clearly hinder quality of life.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>1. For people with schizophrenia<BR/>There is insufficient evidence that use of DHEA with antipsychotic drugs is associated with improvement in mental or global functioning. Use of DHEA should only be agreed to in the context of a randomised trial. </P>
<P>2. For clinicians<BR/>There is no evidence that DHEA use with antipsychotic drugs is any better than use of antipsychotic drugs alone. Currently, this treatment is experimental. </P>
<P>3. For managers/policy makers<BR/>There are no data on service outcomes and no medium or long term data. Until these data become available it would be understandable if managers and policy makers continue to consider adjunctive DHEA to be supportable only within the context of an evaluative study.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>1. General<BR/>If the CONSORT recommendations (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>) had been complied with much more data would have been available. Allocation concealment is essential for the result of a trial to be considered valid and gives the assurance that selection bias is kept to the minimum. Well-described and tested blinding could have encouraged confidence in the control of performance and detection bias. It is also important to know how many, and from which groups, people were withdrawn, in order to evaluate exclusion bias. It would have been helpful if authors had presented data in a useful manner which reflects association between intervention and outcome, for example, relative risk, odds-ratio, risk or mean differences, as well as raw numbers. Binary outcomes should be calculated in preference to continuous results, as they are easier to interpret. If p-values are used, the exact value should be reported.</P>
<P>2. Specific<BR/>If future trials are conducted these should not only be adequately powered and long, but in our opinion should also adhere to a pragmatic design in order to increase applicability. Methods should involve adequate concealment of allocation and follow up. Participants should be people recognisable in everyday life and not those who are so strictly diagnosed as to render them unrecognisable to routine care. Interventions should involve standard doses of DHEA and a control drug that is a real choice in the context of the study. Outcomes should be measured over months rather than weeks as this is the usual period a person would be asked to take the drug. Rating scales need to be validated, clinically meaningful, and outcomes pre-defined. Routine outcomes such as relapse, employment, living independently, satisfaction with care, serious or troubling adverse effects can all be easily recorded without the use of scales. We have outlined such a design in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>With thanks to Judy Wright, Jun Xia, Tessa Grant, John Rathbone and Clive Adams of the Cochrane Schizophrenia Group, University of Leeds, Leeds, UK for their kind help.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Ajit Kumar - none known.</P>
<P>Alby Elias - none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Alby Elias - developed the protocol, selected studies, data extracted, analysed data and wrote the report.</P>
<P>Ajit Kumar - helped with the protocol, selected studies, data extracted, analysed data and wrote the report.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-05 15:46:58 +0000" MODIFIED_BY="[Empty name]">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Nachshoni-2005" NAME="Nachshoni 2005" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nachshoni T, Ebert T, Abramovitch Y, Asael-Amir MM, Weizman A, Kotler M, Strous RD</AU>
<TI>The effect of DHEA administration on extrapyramidal symptoms in schizophrenia: a randomized double blind placebo controlled trial</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>Suppl. 2</NO>
<PG>S135</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="P.2.014"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nachshoni T, Ebert T, Abramovitch Y, Assael-Amir M, Kotler M, Maayan R, Weizman A, Strous RD</AU>
<TI>Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>79</VL>
<NO>2-3</NO>
<PG>251-6</PG>
<CY>Netherlands</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16126372"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ritsner-2006" NAME="Ritsner 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ritsner MS, Gibel A, Ratner Y, Tsinovoy G, Strous RD</AU>
<TI>Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>5</NO>
<PG>495-9</PG>
<CY>United States</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 2006455448+ADs- PsycINFO 2006-12636-009"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strous-2002" NAME="Strous 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strous R, Maayan R, Lapidus R, Stryjer R, Lustig M, Kotler M, Weizman A</AU>
<TI>Use of dehydro--epiandrosterone in the management of negative symptoms of schizophrenia</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>Suppl 3</NO>
<PG>S286</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Hallo P.2.074"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strous RD, Maayan R, Kotler M, Weizman A</AU>
<TI>Hormonal profile effects following dehydroepiandrosterone (DHEA) administration to schizophrenic patients</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>2005</YR>
<VL>28</VL>
<NO>6</NO>
<PG>265-9</PG>
<CY>United States</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16340380"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strous RD, Maayan R, Lapidus R, Stryjer R, Lustig M, Kotler M, Weizman A</AU>
<TI>Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2003</YR>
<VL>60</VL>
<PG>133-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12578430"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Brambilla-1979" NAME="Brambilla 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brambilla F, Scarone S, Ponzano M, Maffei C, Nobile P, Rovere C, Guastalla A</AU>
<TI>Catecholaminergic drugs in chronic schizophrenia</TI>
<SO>Neuropsychobiology</SO>
<YR>1979</YR>
<VL>5</VL>
<NO>4</NO>
<PG>185-200</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="375121"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cotes-1978" NAME="Cotes 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cotes PM, Crow TJ, Johnstone EC, Bartlett W, Bourne RC</AU>
<TI>Neuroendocrine changes in acute schizophrenia as a function of clinical state and neuroleptic medication</TI>
<SO>Psychological Medicine</SO>
<YR>1978</YR>
<VL>8</VL>
<NO>4</NO>
<PG>657-65</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="364517"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ishigooka-1991" NAME="Ishigooka 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ishigooka J, Wakatabe H, Murasaki M, Miura S</AU>
<TI>Phase I study of risperidone, a new antipsychotic drug of benzisoxazol derivative</TI>
<SO>Rinsho Hyoka (Clinical Evaluation)</SO>
<YR>1991</YR>
<VL>19</VL>
<NO>1</NO>
<PG>93-163</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CENTRAL CN-00301233; CENTRAL JRCT 91W1962E003; CENTRAL JICST-E 91A0629572"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kinon-2006" NAME="Kinon 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kinon BJ, Ahl J, Liu-Seifert H, Maguire GA</AU>
<TI>Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine</TI>
<SO>Psychoneuroendocrinology</SO>
<YR>2006</YR>
<VL>31</VL>
<NO>5</NO>
<PG>577-88</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16488084"/>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE 2006206251"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knegtering-2004" NAME="Knegtering 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knegtering R, Castelein S, Bous H, Van Der Linde J, Bruggeman R, Kluiter H, Van Den Bosch RJ</AU>
<TI>A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>1</NO>
<PG>56-61</PG>
<CY>United States of America</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="EMBASE: 2004050225"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ko-2006" NAME="Ko 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ko YH, Joe SH, Jung SW, Lee CH, Jung HG</AU>
<TI>Beneficial effect of short-term testosterone adjuvant treatment for negative symptoms of male schizophrenia</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S376</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="P.3.a.022"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kulkarni-2002" NAME="Kulkarni 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kulkarni J, de Castella A, Downey M, Taffe J, Fitzgerald P</AU>
<TI>Estrogen-a useful adjunct in the treatment of men with schizophrenia?</TI>
<SO>Schizophrenia Research</SO>
<YR>2002</YR>
<VL>53</VL>
<NO>3 Suppl 1</NO>
<PG>10</PG>
<PB>Elsevier Science B.V</PB>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="112838"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kulkarni-2005" NAME="Kulkarni 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kulkarni J, de Castella A</AU>
<TI>Estrogen treatment in women with schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>512-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="112838"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poyurovsky-2003" NAME="Poyurovsky 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Poyurovsky M, Maayan R, Gil-Ad I, Weizman A, Weizman R</AU>
<TI>Reboxetine attenuates weight gain and increases dehydroepiandrosterone levels in olanzapine- treated schizophrenia patients</TI>
<SO>156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA</SO>
<YR>2003</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="[NR202]"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rinieris-1988" NAME="Rinieris 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rinieris P, Hatzimanolis J, Markianos M, Stefanis C</AU>
<TI>Effects of 4 weeks treatment with chlorpromazine and-or trihexyphenidyl on the pituitary gonadal axis in male paranoid schizophrenics</TI>
<SO>European Archives of Psychiatry and Neurological Sciences</SO>
<YR>1988</YR>
<VL>237</VL>
<NO>4</NO>
<PG>189-93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="PsycINFO 76-16624"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sackler-1951" NAME="Sackler 1951" YEAR="1951">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sackler MD, Sackler RR, Sackler AM, van Ophujsen JHW</AU>
<TI>Sex steroid therapy in psychiatric disorders: the therapeutic effect of testosterone and estradiol on hospitalized psychotics; clinical findings</TI>
<SO>Acta Psychiatrica et Neurologica Scandinavica</SO>
<YR>1951</YR>
<VL>26</VL>
<PG>415-37</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="[NR202]"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shen-2001" NAME="Shen 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shen G, Han J, Song L</AU>
<TI>A comparative the results of serum testosterone levels in different age-group of male schizophrenics</TI>
<SO>Sichuan Mental Health</SO>
<YR>2001</YR>
<VL>14</VL>
<NO>4</NO>
<PG>205-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="MEDI0201"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Song-2002" NAME="Song 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Song J, Guo J, Shen G</AU>
<TI>A comparative study of sexual hormones in patients with some mental disorders</TI>
<SO>Journal of Clinical Psychological Medicine</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>3</NO>
<PG>137-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="MEDI0208"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strous-2006" NAME="Strous 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strous RD, Stryjer R, Maayan R, Gal G, Eisner D, Weizman A</AU>
<TI>Amelioration of symptomatology, Parkinsonism and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in schizophrenia</TI>
<SO>Journal of the European College of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>Suppl 4</NO>
<PG>S408</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="P.3.c.022"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-von-Bahr-1991" NAME="von Bahr 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>von Bahr C, Wiesel FA, Movin G, Eneroth P, Jansson P, Nilsson L, Ogenstad S</AU>
<TI>Neuroendocrine responses to single oral doses of remoxipride and sulpiride in healthy female and male volunteers</TI>
<SO>Psychopharmacology</SO>
<YR>1991</YR>
<VL>103</VL>
<NO>4</NO>
<PG>443-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="91288734"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-05 15:46:58 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-05 15:46:58 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andreasen-1985" NAME="Andreasen 1985" TYPE="JOURNAL_ARTICLE">
<AU>Andreasen NC.</AU>
<TI>Negative syndrome in schizophrenia-strategies for long term management</TI>
<SO>Advances in Biochemistry and Psychopharmacology</SO>
<YR>1985</YR>
<VL>40</VL>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bland-1997" NAME="Bland 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bland JM</AU>
<TI>Statistics notes. Trials randomised in clusters</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boissel-1999" NAME="Boissel 1999" TYPE="JOURNAL_ARTICLE">
<AU>Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buysey M, Boutitie F, Nony P, Haugh M, Mignot G</AU>
<TI>The problem of therapeutic efficacy indises. 3. Comparison of indises and their use</TI>
<SO>Therapie</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>4</NO>
<PG>405-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1994" NAME="Carpenter 1994" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT Jr, Buchanan RW</AU>
<TI>Schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<PG>681-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chouinard-1980" NAME="Chouinard 1980" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Ross-Chouinard A, Annable L, Jones BD</AU>
<TI>The Extrapyramidal Symptom Rating Scale</TI>
<SO>Canadian Journal of Neurological Science</SO>
<YR>1980</YR>
<VL>7</VL>
<PG>233</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crow-1980" NAME="Crow 1980" TYPE="JOURNAL_ARTICLE">
<AU>Crow TJ</AU>
<TI>Positive and Negative Symptoms and the role of dopamine</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1980</YR>
<VL>137</VL>
<PG>183-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2000" NAME="Deeks 2000" TYPE="CONFERENCE_PROC">
<AU>Deeks J</AU>
<TI>Issues in the selection of meta-analysis for binary data</TI>
<SO>Abstracts in 8th Cochrane Colloquium , 2000, October 25-28, Cape Town, South Africa</SO>
<YR>2000</YR>
<ED>Cochrane Collaborators</ED>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dilling-2000" NAME="Dilling 2000" TYPE="BOOK">
<AU>Dilling H, Mombour W,Schmidt MH</AU>
<SO>WHO Internatioanale Klassifikation Psychischer Storungen ICD-10 Kapitel V(F) Klinisch-diagnostische Lietlinien</SO>
<YR>2000</YR>
<PB>Verlag Hans Huber</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Divine-1992" NAME="Divine 1992" TYPE="JOURNAL_ARTICLE">
<AU>Divine GW, Brown JT, Frazier LM</AU>
<TI>The unit of analysis error in studies about physicians' patient care behavior</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1992</YR>
<VL>7</VL>
<NO>6</NO>
<PG>623-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-2002" NAME="Donner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Donner A, Klar N</AU>
<TI>Issues in the meta-analysis of cluster randomized trials</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>2971-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duggan-2002" MODIFIED="2008-11-05 15:46:58 +0000" MODIFIED_BY="[Empty name]" NAME="Duggan 2002" TYPE="COCHRANE_REVIEW">
<AU>Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S</AU>
<TI>Olanzapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons Ltd</PB>
<CY>Chichester</CY>
<IDENTIFIERS MODIFIED="2008-11-05 15:46:58 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-05 15:46:58 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001359.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gerlach-1993" NAME="Gerlach 1993" TYPE="JOURNAL_ARTICLE">
<AU>Gerlach J, Korsgaard S, Clemmesen P, Lauersen AM, Magelund G, Noring U, Povlsen UJ, Bech P, Casey DE</AU>
<TI>The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity</TI>
<SO>Acta Pscyhiat Scand</SO>
<YR>1993</YR>
<VL>87</VL>
<NO>4</NO>
<PG>244-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goyal-2004" NAME="Goyal 2004" TYPE="JOURNAL_ARTICLE">
<AU>Goyal 2003, Sagar R, Ammini AC, Khurana ML, Alias AG</AU>
<TI>Negative correlation between negtaive symtoms of schizophrenia and testosterone levels</TI>
<SO>Annals of the New York Academy of Science</SO>
<YR>2004</YR>
<VL>1032</VL>
<PG>291-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gulliford-1999" NAME="Gulliford 1999" TYPE="JOURNAL_ARTICLE">
<AU>Gulliford MC</AU>
<TI>Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>876-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy U</AU>
<SO>ECDEU assessment manual for psychopharmacology</SO>
<YR>1976</YR>
<EN>Revised</EN>
<PB>National Institute of Mental Health</PB>
<CY>Rockville</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harris-2001" NAME="Harris 2001" TYPE="JOURNAL_ARTICLE">
<AU>Harris DS, Wolkowitz OM, Reus VI</AU>
<TI>Movement disorder, memory, psychiatric symproms and serum DHEA levels in schizophrenic and schizoaffective disorders</TI>
<SO>World Journal of Biological Psychiatry</SO>
<YR>2001</YR>
<VL>2</VL>
<NO>2</NO>
<PG>99-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" MODIFIED="2008-11-05 15:43:50 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins JPT, Green S</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Huber-2005" NAME="Huber 2005" TYPE="JOURNAL_ARTICLE">
<AU>Huber TJ, Tettenborn C, Leifke E, Emrich HM</AU>
<TI>Sex hormones in psychotic men</TI>
<SO>Psychoneuroendocrinology</SO>
<YR>2005</YR>
<VL>30</VL>
<NO>1</NO>
<PG>111-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Joy-2002" MODIFIED="2008-11-05 15:43:40 +0000" MODIFIED_BY="[Empty name]" NAME="Joy 2002" TYPE="COCHRANE_REVIEW">
<AU>Joy CB, Admas CE, Lawrie SM</AU>
<TI>Haloperidol versus placebo in schizophrenia (Cochrane review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichetster, UK</CY>
<IDENTIFIERS MODIFIED="2008-11-05 15:43:40 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-05 15:43:40 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003082.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kay-1987" NAME="Kay 1987" TYPE="JOURNAL_ARTICLE">
<AU>Kay SR, Fiszbein A, and Opler LA</AU>
<TI>The positive and negative syndrome scale (PANSS) for schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1987</YR>
<VL>13</VL>
<PG>261-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kennedy-2002" MODIFIED="2008-11-05 15:46:16 +0000" MODIFIED_BY="[Empty name]" NAME="Kennedy 2002" TYPE="COCHRANE_REVIEW">
<AU>Kennedy E, Song F, Hunter R, Clarke A, Gilbody S</AU>
<TI>Risperidone versus typical anipsychotic medication for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2008-11-05 15:46:16 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-05 15:46:16 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002306"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005a" NAME="Leucht 2005a" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>Clinical implications of Brief Psychiatric Rating Scale Scores</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2005</YR>
<VL>187</VL>
<PG>366-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leucht-2005b" NAME="Leucht 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R</AU>
<TI>What does the PANSS mean?</TI>
<SO>Schizophrenia Research</SO>
<YR>2005</YR>
<VL>79</VL>
<PG>231-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lingjaerde-1987" NAME="Lingjaerde 1987" TYPE="JOURNAL_ARTICLE">
<AU>Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K</AU>
<TI>The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1987</YR>
<VL>76</VL>
<NO>334</NO>
<PG>100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-2000" NAME="Marshall 2000" TYPE="JOURNAL_ARTICLE">
<AU>Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M</AU>
<TI>Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>249-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schultz KF, Altman DG</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomised trials</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>357</VL>
<PG>1191-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mota-Neto-2002" MODIFIED="2008-11-05 15:45:19 +0000" MODIFIED_BY="[Empty name]" NAME="Mota Neto 2002" TYPE="COCHRANE_REVIEW">
<AU>Mota Neto JIS, Lima MS, Soares BGO</AU>
<TI>Amisulpride for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2008-11-05 15:45:19 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-05 15:45:19 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001357"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ritsner-2005" NAME="Ritsner 2005" TYPE="JOURNAL_ARTICLE">
<AU>Ritsner M, Gibel A, Maayan R, Ratner Y, Ram E, Biadsy H, Modai I, Weizman A</AU>
<TI>Cortisol/DHEA ratio and response to antipsychotic treatment in schizophrenia</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>30</VL>
<NO>10</NO>
<PG>1913-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rivaz_x002d_Vasquez-2003" NAME="Rivaz-Vasquez 2003" TYPE="JOURNAL_ARTICLE">
<AU>Rivaz-Vasquez RA</AU>
<TI>Aripiprazole: a novel antipsychotic with novel prporties</TI>
<SO>Professional psychology:reserach and practice</SO>
<YR>2003</YR>
<VL>34</VL>
<NO>1</NO>
<PG>18-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence for Bias:dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Silver-2005" NAME="Silver 2005" TYPE="JOURNAL_ARTICLE">
<AU>Silver H, Knoll G, Isakov V, Goodman C, Finkelstein Y</AU>
<TI>Blood DHEA concentrations correlate with cognitive function in chronic schizophrenic patients: a pilot study</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>2005</YR>
<VL>39</VL>
<NO>6</NO>
<PG>569-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Strous-2003" NAME="Strous 2003" TYPE="JOURNAL_ARTICLE">
<AU>Strous RD, Mayaan R, Lapidus R, Stryjer R, Lustig M, Kotler M, Weizman A</AU>
<TI>Dehydroepiandrosterone augmentation in the management of negative, depressive and anxiety symtoms in schizophrenia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>2</NO>
<PG>133-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Taherianfard-2005" NAME="Taherianfard 2005" TYPE="JOURNAL_ARTICLE">
<AU>Taherianfard M, Shariaty M</AU>
<TI>Evaluation of steroid hormones in schizophrenic patients</TI>
<SO>Indian Journal of Medical Science</SO>
<YR>2004</YR>
<VL>58</VL>
<NO>1</NO>
<PG>3-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thornley-2002" MODIFIED="2008-11-05 15:44:41 +0000" MODIFIED_BY="[Empty name]" NAME="Thornley 2002" TYPE="COCHRANE_REVIEW">
<AU>Thornley B, Adams CE, Awad G</AU>
<TI>Chlorpromazine versus placebo for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS MODIFIED="2008-11-05 15:44:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-05 15:44:41 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000284.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ukoumunne-1999" NAME="Ukoumunne 1999" TYPE="JOURNAL_ARTICLE">
<AU>Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ</AU>
<TI>Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review</TI>
<SO>Health Technology Assessment</SO>
<YR>1999</YR>
<VL>3</VL>
<NO>5</NO>
<PG>1-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wahlbeck-2001" NAME="Wahlbeck 2001" TYPE="JOURNAL_ARTICLE">
<AU>Wahlbeck K, Tuunainen A, Ahokas A, Leucht S</AU>
<TI>Dropout rates randomized antipsychotic drug trials</TI>
<SO>Psychopharmacology</SO>
<YR>2001</YR>
<VL>155</VL>
<PG>230-3</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Nachshoni-2005">
<CHAR_METHODS>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 1 week.<BR/>Design: single centre.<BR/>Country: Israel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, paranoid, disorganised, residual, undifferentiated and schizoaffective disorder (DSM-IV). <BR/>N=34.<BR/>Age: range 19-64 years.<BR/>Sex: 9 females, 25 males.<BR/>Inclusion criteria: aged 18-65 years; patients with any form of extrapyramidal symptoms.<BR/>Exclusion criteria: patients receiving steroids, pregnant, engaged in any substance abuse or with any significant medical or neurological illness.<BR/>Setting: inpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. DHEA + antipsychotic: dose DHEA 100 mg (50 mg 8 am &amp; 8 pm). N=18.<BR/>2. Placebo + antipsychotic.N=16.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Mental state: BPRS.<BR/>Adverse effects: SHRSEPS.</P>
<P>Unable to use - <BR/>Blood DHEA level (no usable data).<BR/>Global state: CGI (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ritsner-2006">
<CHAR_METHODS>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 12 weeks (6 weeks before crossover).<BR/>Design: crossover, multicentre.<BR/>Country: Israel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, paranoid, disorganised, catatonic and undifferentiated, schizoaffective disorder (DSM-IV). <BR/>N=62.<BR/>Age: mean 36.4 years, range 20-53 years.<BR/>Sex: 14 female, 41 male, others not reported.<BR/>Inclusion criteria: aged 18-55 years, having DSM-IV criteria for chronic schizophrenia or schizoaffective disorder, and ability and willingness to sign informed consent.<BR/>Exclusion criteria: any evidence of organic brain damage, mental retardation, major medical illness, alcohol or drug abuse, prostate nodules or cancer, symptoms of benign prostatic hypertrophy, pregnancy, or any history of breast or uterine illness.<BR/>Setting: inpatient and outpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. DHEA + antipsychotic: dose DHEA 200 mg/day. N=31.<BR/>2. Placebo + antipsychotic. N=31.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Before crossover.<BR/>Mental state: PANSS.<BR/>Adverse effects: ESRS, AIMS.<BR/>Quality of Life Scale.</P>
<P>Unable to use - <BR/>Visual &amp; movement skills, attention &amp; memory and executive function test (no usable data).<BR/>Serum hormone levels (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Strous-2002">
<CHAR_METHODS>
<P>Allocation: randomised.<BR/>Blindness: double.<BR/>Duration: 6 week.<BR/>Design: single centre.<BR/>Country: Israel.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia, paranoid, disorganised, residual, undifferentiated. disorder (DSM-IV). <BR/>History: duration of illness more than two years.<BR/>N=30.<BR/>Age: mean 37.4 years, range 19-64 years.<BR/>Sex: 12 females, 15 males, others not reported.<BR/>Inclusion criteria: aged 18-70 years; duration of illness longer than 2 years; negative symptoms, a score of at least 25 on the scale for the assessment of negative symptoms (SANS).<BR/>Exclusion criteria: patients with any significant (including prostate illness) or neurological illness, pregnant.<BR/>Setting: inpatient.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. DHEA + antipsychotics*: dose DHEA 25 mg/day (8am) - 2 weeks, 50 mg/day, equally divided doses (8 am &amp; 8 pm) - next 2 weeks, 100 mg/day, equally divided doses (8 am &amp; 8 pm) - next 2 weeks. N=15.<BR/>2. Placebo + antipsychotics*. N=15.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Global state: CGI.<BR/>Mental state: PANSS, SANS, HAM-D, HAM-A.<BR/>Adverse effects. </P>
<P>Unable to use - <BR/>Blood DHEA and DHEA-S level (no usable data).<BR/>Blood cortisol (no usable data).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>* clozapine, fluphenazine, haloperidol, olanzapine, risperidone, zuclopenthixol</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>DHEA - Dehyroepiandrosterone<BR/>DHEA-S - Dehyroepiandrosterone-sulfated</P>
<P>Global state - <BR/>CGI - Clinical Global Impression</P>
<P>Mental state - <BR/>BPRS - Brief Psychiatric Rating Scale<BR/>HAM-D - Hamilton Scale for Depression<BR/>HAM-A - Hamilton Scale for Anxiety<BR/>PANSS - Positive and Negative Syndrome Scale<BR/>SANS - Scale for the Assessment of Negative Symptoms</P>
<P>Adverse events - <BR/>AIMS - Abnormal Involuntary Movement Scale<BR/>ESRS - Extrapyramidal Symptom Rating Scale<BR/>SHRSEPS - Sanct Hans rating scale for extra pyramidal syndromes</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Brambilla-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomisation not clear.<BR/>Participants: males with chronic hebephrenic schizophrenia.<BR/>Interventions: L-dopa, carbodopa including placebo versus L-dopa, carbodopa, imipramine including placebo versus apomorphine including placebo versus L-dopa, carbodopa, apomorphine including placebo, no intervention with DHEA or any other form of testosterone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cotes-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with acute schizophrenia.<BR/>Interventions: alpha flupenthixol versus beta flupenthixol versus placebo, no use of DHEA or any other form of testosterone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ishigooka-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomisation not clear.<BR/>Participants: healthy volunteers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kinon-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, schizophreniform disorder, or schizoaffective disorder.<BR/>Interventions: switching to olanzapine from conventional antipsychotics or risperidone, no use of DHEA or any other form of testosterone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Knegtering-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with psychotic disorder, schizophreniform disorder, schizophrenia, schizoaffective disorder.<BR/>Interventions: quetiapine versus risperidone, no use of DHEA or any other form of testosterone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ko-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with chronic schizophrenia.<BR/>Interventions: antipsychotics &amp; testosterone versus antipsychotics &amp; placebo.<BR/>Outcome: PANSS, SANS, Calgary depression scale for schizophrenia, extrapyramidal symptoms scale, serum hormone levels, no usable data given.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kulkarni-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: men with acute schizophrenia.<BR/>Intervention: antipsychotic and estradiol versus antipsychotic and placebo, no use of DHEA or any other form of testosterone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kulkarni-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomisation not clear.<BR/>Participants: women with schizophrenia.<BR/>Intervention: antipsychotic and transdermal estradiol versus antipsychotic and transdermal placebo, no use of DHEA or any other form of testosterone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Poyurovsky-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia.<BR/>Intervention: olanzapine and reboxetine versus olanzapine and placebo, no use of DHEA or any other form of testosterone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rinieris-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with chronic (subchronic) paranoid schizophrenia.<BR/>Intervention: chlorpromazine versus chlorpromazine and trihexyphenidyl versus trihexyphenidyl, no use of DHEA or any other form of testosterone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sackler-1951">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with schizophrenia, psychosis, depression and manic-depressive disorder.<BR/>Intervention: different doses of testosterone + estradiol described as massive and submassive dosages for two groups, no concomitant use of antipsychotics.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shen-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Song-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Strous-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: people with chronic schizophrenia.<BR/>Interventions: olanzapine &amp; DHEA versus olanzapine &amp; placebo.<BR/>Outcome: PANSS, SANS, extrapyramidal symptoms scale, blood biochemistry, no useable data given.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-von-Bahr-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: healthy volunteers.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>DHEA - dehydroepiandrosterone</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Nachshoni-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ritsner-2006">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Strous-2002">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Suggested design of study</TITLE>
<TABLE COLS="5" ROWS="2">
<TR>
<TH>
<P>Type of study</P>
</TH>
<TH>
<P>Patients</P>
</TH>
<TH>
<P>Interventions</P>
</TH>
<TH>
<P>Outcomes</P>
</TH>
<TH>
<P>Notes</P>
</TH>
</TR>
<TR>
<TD>
<P>Allocation: randomised, process clearly described.<BR/>Blindness: double, and tested.<BR/>Analyses: intention-to-treat<BR/>Duration: 1 year follow-up.<BR/>Design: parallel group.</P>
</TD>
<TD>
<P>Diagnosis: people with schizophrenia or related disorders with persistant postive or negative symptoms.<BR/>N=300.<BR/>Age: over 16 years of age.<BR/>Sex: men &amp; women.</P>
</TD>
<TD>
<P>1. DHEA + antipsychotic: dose DHEA 200 mg/day.<BR/>2. Placebo + antipsychotic.</P>
</TD>
<TD>
<P>1. Service utilisation (e.g. hospital admission, days in hospital).<BR/>2. Mental state and behaviour (use appropriate scales, and report endpoint scores and validated subscale scores only).<BR/>3. Clinical global response (e.g. relapse, leaving the study early, endpoint score in global state improvement).<BR/>4. Social functioning (e.g. social impairment, employment status, independent living; report endpoint scores of scales used).<BR/>5. Quality of life (e.g. clinically inportant change, report endpoint scores of scale used). <BR/>6. Family outcome (e.g. family burden, satisfaction with care, ecomonic outcomes/cost of care).<BR/>7. Satisfaction with treatment <BR/>8. Adverse effects (e.g clinically important general adverse effects, mortality, if scales are used report endpoint scores). <BR/>
</P>
</TD>
<TD>
<P>Outcomes could be grouped into <BR/> short term (up to 12 weeks)<BR/> medium term (13 to 26 weeks)<BR/> long term (over 26 weeks)<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>DHEA + antipsychotics vs PLACEBO + antipsychotics (all short term)</NAME>
<CONT_OUTCOME CHI2="0.065392957178512" CI_END="-0.010673777371944249" CI_START="-0.7661703585146211" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.38842206794328266" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.798166694071873" P_Q="0.798166694071873" P_Z="0.043868475449563654" Q="0.065392957178512" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="30" TOTAL_2="24" UNITS="" WEIGHT="200.0" Z="2.015345358195956">
<NAME>Global state: Average endpoint global impression (CGI, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.06421286329991471" CI_START="-0.924212863299915" DF="0.0" EFFECT_SIZE="-0.43000000000000016" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.01" NO="1" P_CHI2="1.0" P_Z="0.08813723627854565" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="12" WEIGHT="100.0" Z="1.705306712829886">
<NAME>improvement</NAME>
<CONT_DATA CI_END="0.06421286329991471" CI_START="-0.924212863299915" EFFECT_SIZE="-0.43000000000000016" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="3.83" ORDER="19405" SD_1="0.74" SD_2="0.57" SE="0.252154053440881" STUDY_ID="STD-Strous-2002" TOTAL_1="15" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2558292678253735" CI_START="-0.9158292678253737" DF="0.0" EFFECT_SIZE="-0.33000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" NO="2" P_CHI2="1.0" P_Z="0.26956901428554403" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="12" WEIGHT="100.0" Z="1.104055653107136">
<NAME>severity of illness</NAME>
<CONT_DATA CI_END="0.2558292678253735" CI_START="-0.9158292678253737" EFFECT_SIZE="-0.33000000000000007" ESTIMABLE="YES" MEAN_1="4.33" MEAN_2="4.66" ORDER="19406" SD_1="0.61" SD_2="0.88" SE="0.29889797590482275" STUDY_ID="STD-Strous-2002" TOTAL_1="15" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.2605186476472616" CI_END="5.461754842090355" CI_START="-13.776205814002616" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.15722548595613" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.60976410279363" P_Q="1.0" P_Z="0.3969524889975783" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="44" TOTAL_2="38" UNITS="" WEIGHT="99.99999999999999" Z="0.847076503975013">
<NAME>Mental state: 1a. General symptoms - average endpoint score (PANSS, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.596953523918074" CI_START="-16.99695352391808" EFFECT_SIZE="-5.700000000000003" ESTIMABLE="YES" MEAN_1="84.2" MEAN_2="89.9" ORDER="19407" SD_1="20.7" SD_2="21.9" SE="5.763857710155393" STUDY_ID="STD-Ritsner-2006" TOTAL_1="29" TOTAL_2="26" WEIGHT="72.49956302952101"/>
<CONT_DATA CI_END="18.252530049648662" CI_START="-18.432530049648655" EFFECT_SIZE="-0.0899999999999963" ESTIMABLE="YES" MEAN_1="52.2" MEAN_2="52.29" ORDER="19408" SD_1="21.8" SD_2="25.9" SE="9.358605665375585" STUDY_ID="STD-Strous-2002" TOTAL_1="15" TOTAL_2="12" WEIGHT="27.50043697047897"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="6.393269119823932" CI_START="-8.79326911982393" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1999999999999993" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.7567569193011194" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="0.3097423184050929">
<NAME>Mental state: 1b. General symptoms - average endpoint score (BPRS, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.393269119823932" CI_START="-8.79326911982393" EFFECT_SIZE="-1.1999999999999993" ESTIMABLE="YES" MEAN_1="21.0" MEAN_2="22.2" ORDER="19409" SD_1="12.5" SD_2="8.3" SE="3.874188086984592" STUDY_ID="STD-Nachshoni-2005" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.7658366844052167" CI_START="-3.7658366844052167" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.4785520694306743" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="26" UNITS="" WEIGHT="100.0" Z="0.70863330275104">
<NAME>Mental state: 2. Positive symptoms - average pre-crossover score (PANSS, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.7658366844052167" CI_START="-3.7658366844052167" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="14.0" ORDER="19410" SD_1="4.9" SD_2="5.5" SE="1.4111670960394085" STUDY_ID="STD-Ritsner-2006" TOTAL_1="29" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.572404943020396" CI_START="0.08907776603213849" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.22580645161290322" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.24229662453278392" LOG_CI_START="-1.0502306831072479" LOG_EFFECT_SIZE="-0.6462636538200158" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.001715399054635598" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="3.1355367992269145">
<NAME>Mental state: 3a. Negative symptoms not improved (SANS)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5724049430203959" CI_START="0.08907776603213849" EFFECT_SIZE="0.22580645161290322" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="15" LOG_CI_END="-0.242296624532784" LOG_CI_START="-1.0502306831072479" LOG_EFFECT_SIZE="-0.6462636538200158" ORDER="19411" O_E="0.0" SE="0.47458446534473053" STUDY_ID="STD-Strous-2002" TOTAL_1="15" TOTAL_2="15" VAR="0.22523041474654376" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.782784485700665" CI_START="-6.382784485700666" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.3000000000000007" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.2695375815845532" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="26" UNITS="" WEIGHT="100.0" Z="1.104128121440263">
<NAME>Mental state: 3b. Negative symptoms - average pre-crossover score (PANSS, high=poor)</NAME>
<GROUP_LABEL_1>treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.782784485700665" CI_START="-6.382784485700666" EFFECT_SIZE="-2.3000000000000007" ESTIMABLE="YES" MEAN_1="27.4" MEAN_2="29.7" ORDER="19412" SD_1="7.0" SD_2="8.3" SE="2.083091586327682" STUDY_ID="STD-Ritsner-2006" TOTAL_1="29" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.07" NO="7" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Mental state: 3c. Negative symptoms - average endpoint score (SANS, high=poor, skewed data)</NAME>
<TR>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_DATA ORDER="9" STUDY_ID="STD-Strous-2002">
<TR>
<TD>
<P>DHEA</P>
</TD>
<TD>
<P>29.9</P>
</TD>
<TD>
<P>25.0</P>
</TD>
<TD>
<P>15</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>35.7</P>
</TD>
<TD>
<P>24.0</P>
</TD>
<TD>
<P>12</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.08" NO="8" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Mental state: 4. Depression - average endpoint score (HAM-D, high=poor, skewed data)</NAME>
<TR>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_DATA ORDER="10" STUDY_ID="STD-Strous-2002">
<TR>
<TD>
<P>DHEA</P>
</TD>
<TD>
<P>4.13</P>
</TD>
<TD>
<P>4.47</P>
</TD>
<TD>
<P>15</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>7.5</P>
</TD>
<TD>
<P>5.4</P>
</TD>
<TD>
<P>12</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.09" NO="9" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Mental state: 5. Anxiety - average endpoint score (HAM-A, high=poor, skewed data)</NAME>
<TR>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
<TH>
<P>N</P>
</TH>
</TR>
<OTHER_DATA ORDER="11" STUDY_ID="STD-Strous-2002">
<TR>
<TD>
<P>DHEA</P>
</TD>
<TD>
<P>2.13</P>
</TD>
<TD>
<P>2.26</P>
</TD>
<TD>
<P>15</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>5.0</P>
</TD>
<TD>
<P>4.9</P>
</TD>
<TD>
<P>12<BR/>
</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="3.1773413734476654" CI_END="1.3403671945183921" CI_START="0.20688590369120302" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.526595744680851" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" I2="37.05429272682014" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.1272237899376388" LOG_CI_START="-0.6842690992698988" LOG_EFFECT_SIZE="-0.27852265466612997" METHOD="MH" NO="10" P_CHI2="0.20419699836955596" P_Q="0.0" P_Z="0.1784936249735549" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="48" TOTAL_2="46" WEIGHT="200.0" Z="1.3454076536818311">
<NAME>Behaviour: Leaving the study early</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.0384297166882934" CI_END="2.4051719095933124" CI_START="0.2635160866354476" DF="1.0" EFFECT_SIZE="0.7961165048543689" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" I2="50.94263040745716" ID="CMP-001.10.01" LOG_CI_END="0.3811461230048857" LOG_CI_START="-0.5791928676477969" LOG_EFFECT_SIZE="-0.09902337232145553" NO="1" P_CHI2="0.1533683194749369" P_Z="0.6860691257091376" STUDIES="2" TAU2="0.0" TOTAL_1="33" TOTAL_2="31" WEIGHT="100.00000000000001" Z="0.4041952795144716">
<NAME>reason not specified</NAME>
<DICH_DATA CI_END="23.138235225075903" CI_START="0.30733161115954477" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3643302318309927" LOG_CI_START="-0.5123927672864306" LOG_EFFECT_SIZE="0.4259687322722811" ORDER="19416" O_E="0.0" SE="1.102396379610246" STUDY_ID="STD-Nachshoni-2005" TOTAL_1="18" TOTAL_2="16" VAR="1.2152777777777777" WEIGHT="17.47572815533981"/>
<DICH_DATA CI_END="1.7491265621242627" CI_START="0.09147422688823888" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.24282123500387298" LOG_CI_START="-1.038701252347948" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="19417" O_E="0.0" SE="0.752772652709081" STUDY_ID="STD-Strous-2002" TOTAL_1="15" TOTAL_2="15" VAR="0.5666666666666667" WEIGHT="82.5242718446602"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5140742356037356" CI_START="0.02641878387425968" DF="0.0" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="0.18014716930056518" LOG_CI_START="-1.5780871779726027" LOG_EFFECT_SIZE="-0.6989700043360187" NO="2" P_CHI2="1.0" P_Z="0.11915467176373172" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0" Z="1.5583315579030255">
<NAME>due to uncooperativeness or getting worse</NAME>
<DICH_DATA CI_END="1.5140742356037356" CI_START="0.02641878387425968" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.18014716930056518" LOG_CI_START="-1.5780871779726027" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="19418" O_E="0.0" SE="1.0327955589886444" STUDY_ID="STD-Strous-2002" TOTAL_1="15" TOTAL_2="15" VAR="1.0666666666666667" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.152608504141016" CI_START="-8.847391495858984" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.11" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.010861186129704378" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="2.5471335405424664">
<NAME>Adverse effects: 1a. Movement disorder - general symptoms - average score (SHRSEPS, high=poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.152608504141016" CI_START="-8.847391495858984" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="21.5" MEAN_2="26.5" ORDER="19419" SD_1="4.4" SD_2="6.2" SE="1.9629909152447276" STUDY_ID="STD-Nachshoni-2005" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.12" NO="12" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Adverse effects: 1b. Movement disorder - general symptoms - average scores (data skewed, high=poor)</NAME>
<TR>
<TH>
<P>Group</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.12.01" NO="1" STUDIES="1">
<NAME>Abnormal Involuntary Movement Scale - AIMS</NAME>
<OTHER_DATA ORDER="16" STUDY_ID="STD-Ritsner-2006">
<TR>
<TD>
<P>Treatment</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>1.1</P>
</TD>
<TD>
<P>2.8</P>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>0.8</P>
</TD>
<TD>
<P>2.3</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.12.02" NO="2" STUDIES="1">
<NAME>Extrapyramidal Symptom Rating Scale - ESRS</NAME>
<OTHER_DATA ORDER="17" STUDY_ID="STD-Ritsner-2006">
<TR>
<TD>
<P>Treatment</P>
</TD>
<TD>
<P>29</P>
</TD>
<TD>
<P>4.0</P>
</TD>
<TD>
<P>6.8</P>
</TD>
</TR>
<TR>
<TD>
<P>Control</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>5.5</P>
</TD>
<TD>
<P>8.5</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="12.288263396809386" CI_START="0.5786912992894906" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="1.0894905118146239" LOG_CI_START="-0.23755304727006143" LOG_EFFECT_SIZE="0.4259687322722811" METHOD="MH" NO="13" P_CHI2="1.0" P_Q="0.0" P_Z="0.20829751649172024" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="36" TOTAL_2="32" WEIGHT="200.0" Z="1.2582606924669573">
<NAME>Adverse effects: 2a. Movement disorder - specific symptoms (SHRSEPS)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="23.138235225075903" CI_START="0.30733161115954477" DF="0.0" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-001.13.01" LOG_CI_END="1.3643302318309927" LOG_CI_START="-0.5123927672864306" LOG_EFFECT_SIZE="0.4259687322722811" NO="1" P_CHI2="1.0" P_Z="0.37361375466718383" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="16" WEIGHT="100.0" Z="0.8897246681438666">
<NAME>akathisia</NAME>
<DICH_DATA CI_END="23.138235225075903" CI_START="0.30733161115954477" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3643302318309927" LOG_CI_START="-0.5123927672864306" LOG_EFFECT_SIZE="0.4259687322722811" ORDER="19422" O_E="0.0" SE="1.102396379610246" STUDY_ID="STD-Nachshoni-2005" TOTAL_1="18" TOTAL_2="16" VAR="1.2152777777777777" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="23.138235225075903" CI_START="0.30733161115954477" DF="0.0" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-001.13.02" LOG_CI_END="1.3643302318309927" LOG_CI_START="-0.5123927672864306" LOG_EFFECT_SIZE="0.4259687322722811" NO="2" P_CHI2="1.0" P_Z="0.37361375466718383" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="16" WEIGHT="100.0" Z="0.8897246681438666">
<NAME>parkinsonism</NAME>
<DICH_DATA CI_END="23.138235225075903" CI_START="0.30733161115954477" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3643302318309927" LOG_CI_START="-0.5123927672864306" LOG_EFFECT_SIZE="0.4259687322722811" ORDER="19423" O_E="0.0" SE="1.102396379610246" STUDY_ID="STD-Nachshoni-2005" TOTAL_1="18" TOTAL_2="16" VAR="1.2152777777777777" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.5528399197773686" CI_START="-7.447160080222631" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.14" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.02294830782269944" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="15" UNITS="" WEIGHT="100.0" Z="2.27429413073671">
<NAME>Adverse effects: 2b. Movement disorder - specfic symptoms - mean parkinsonism score (UKU, high = poor)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.5528399197773686" CI_START="-7.447160080222631" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="20.2" MEAN_2="24.2" ORDER="19424" SD_1="4.4" SD_2="5.2" SE="1.758787461103056" STUDY_ID="STD-Nachshoni-2005" TOTAL_1="15" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.15" NO="15" ROWS_PER_STUDY="2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Adverse effects: 2c. Movement disorder - specfic symptoms - mean akathisia score (UKU, data skewed, high=poor)</NAME>
<TR>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>N</P>
</TH>
<TH>
<P>Mean</P>
</TH>
<TH>
<P>SD</P>
</TH>
</TR>
<OTHER_DATA ORDER="21" STUDY_ID="STD-Nachshoni-2005">
<TR>
<TD>
<P>DHEA</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>1.1</P>
</TD>
<TD>
<P>2.6</P>
</TD>
</TR>
<TR>
<TD>
<P>Placebo</P>
</TD>
<TD>
<P>15</P>
</TD>
<TD>
<P>1.2</P>
</TD>
<TD>
<P>2.3</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="13.7709042046115" CI_START="-1.3709042046114943" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="6.200000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.16" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.10847998480270003" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="26" UNITS="" WEIGHT="100.0" Z="1.6050628003913454">
<NAME>Quality of life: 1a. Average score as rated by observer (QLS, high=good)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="13.7709042046115" CI_START="-1.3709042046114943" EFFECT_SIZE="6.200000000000003" ESTIMABLE="YES" MEAN_1="68.5" MEAN_2="62.3" ORDER="19426" SD_1="13.1" SD_2="15.3" SE="3.8627772062802292" STUDY_ID="STD-Ritsner-2006" TOTAL_1="29" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5771552218531001" CI_START="-0.17715522185309973" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.17" NO="17" P_CHI2="1.0" P_Q="1.0" P_Z="0.29864629703826184" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="26" UNITS="" WEIGHT="100.0" Z="1.0393407652743316">
<NAME>Quality of life: 1b. Average score as rated by self (Q-LES-Q, high=good)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5771552218531001" CI_START="-0.17715522185309973" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="3.3" ORDER="19427" SD_1="0.6" SD_2="0.8" SE="0.19242966953885488" STUDY_ID="STD-Ritsner-2006" TOTAL_1="29" TOTAL_2="26" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>